Arrowhead Pharmaceuticals, Inc.
ARWR
$21.33
$0.582.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 572.98M | 545.21M | 2.50M | 3.55M | 19.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 572.98M | 545.21M | 2.50M | 3.55M | 19.65M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 572.98M | 545.21M | 2.50M | 3.55M | 19.65M |
| SG&A Expenses | 136.77M | 130.20M | 125.94M | 122.61M | 119.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 680.94M | 663.76M | 628.45M | 604.63M | 566.86M |
| Operating Income | -107.96M | -118.55M | -625.95M | -601.08M | -547.21M |
| Income Before Tax | -157.39M | -152.27M | -648.89M | -612.46M | -548.65M |
| Income Tax Expenses | 1.97M | 2.40M | 649.00K | -2.77M | -1.29M |
| Earnings from Continuing Operations | -159.35 | -154.68 | -649.54 | -609.69 | -547.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 10.93M | 10.71M | 9.82M | 10.20M | 8.73M |
| Net Income | -148.42M | -143.97M | -639.71M | -599.49M | -538.64M |
| EBIT | -107.96M | -118.55M | -625.95M | -601.08M | -547.21M |
| EBITDA | -85.40M | -97.43M | -606.38M | -582.49M | -529.78M |
| EPS Basic | -1.24 | -1.36 | -5.15 | -5.00 | -4.65 |
| Normalized Basic EPS | -0.73 | -0.80 | -3.19 | -3.11 | -2.89 |
| EPS Diluted | -1.27 | -1.39 | -5.16 | -5.01 | -4.66 |
| Normalized Diluted EPS | -0.75 | -0.82 | -3.19 | -3.11 | -2.89 |
| Average Basic Shares Outstanding | 521.61M | 506.77M | 496.69M | 479.26M | 462.11M |
| Average Diluted Shares Outstanding | 522.73M | 507.89M | 496.69M | 479.26M | 462.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |